There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biora Therapeutics (BIOR – Research Report), Rani Therapeutics Holdings (RANI – Research Report) and IO Biotech (IOBT – Research Report) with bullish sentiments.
Biora Therapeutics (BIOR)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Biora Therapeutics today and set a price target of $65.00. The company’s shares closed last Monday at $2.11, close to its 52-week low of $1.95.
According to TipRanks.com, Pantginis ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -15.8% and a 30.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Bioline RX Ltd Sponsored ADR, and Actinium Pharmaceuticals.
Currently, the analyst consensus on Biora Therapeutics is a Moderate Buy with an average price target of $65.00.
See the top stocks recommended by analysts >>
Rani Therapeutics Holdings (RANI)
In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Rani Therapeutics Holdings, with a price target of $22.00. The company’s shares closed last Monday at $6.45, close to its 52-week low of $5.11.
According to TipRanks.com, Kapoor is a 3-star analyst with an average return of 6.7% and a 41.7% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Century Therapeutics, CytomX Therapeutics, and Lyell Immunopharma.
Rani Therapeutics Holdings has an analyst consensus of Strong Buy, with a price target consensus of $20.25.
IO Biotech (IOBT)
In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on IO Biotech, with a price target of $10.00. The company’s shares closed last Monday at $2.45, close to its 52-week low of $2.15.
According to TipRanks.com, Bodnar has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -17.5% and a 21.0% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Gracell Biotechnologies, TransCode Therapeutics, and Olema Pharmaceuticals.
Currently, the analyst consensus on IO Biotech is a Moderate Buy with an average price target of $10.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BIOR: